Combined effect of protein fusion and signal sequence greatly enhances the production of recombinant human GM-CSF in Escherichia coli

Molecular Biotechnology

Volumn 30, Issue 2, 2005, Pages 103-115

  Bhattacharya, Palash ^b   Pandey, Gaurav ^b   Srivastava, Poonam ^b   Mukherjee, Krishna Jyoti ^a  

^a JAWAHARLAL NEHRU UNIVERSITY   (India)

^b NONE

Author keywords

E. coli; GM CSF; High cell density; Protein fusion; Signal sequence

Indexed keywords

DEGRADATION; ESCHERICHIA COLI; MALTOSE; PROTEINS; TOXICITY;

GRANULOCYTE-MACROPHAGE COLONY-STIMULATING FACTOR (GM-CSF); HEMATOPOIETIC GROWTH FACTOR; STEM CELL TRANSPLANTATION; THERAPEUTIC AGENTS;

BIOTECHNOLOGY;

MALTOSE BINDING PROTEIN; RECOMBINANT GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR;

AMINO TERMINAL SEQUENCE; ARTICLE; BONE MARROW; BONE MARROW TRANSPLANTATION; CELL DENSITY; ESCHERICHIA COLI; GENE FUSION; GENE SEQUENCE; NONHUMAN; NUCLEOTIDE SEQUENCE; PROTEIN ANALYSIS; PROTEIN DEGRADATION; PROTEIN EXPRESSION; SIGNAL TRANSDUCTION; STEM CELL TRANSPLANTATION;

CARRIER PROTEINS; CODON; ESCHERICHIA COLI; GRANULOCYTE MACROPHAGE COLONY-STIMULATING FACTORS, RECOMBINANT; HUMANS; INDUSTRIAL MICROBIOLOGY; PERIPLASM; PLASMIDS; PROTEIN SORTING SIGNALS; RECOMBINANT FUSION PROTEINS; RNA STABILITY; RNA, MESSENGER;

ESCHERICHIA COLI;

EID: 22344447125     PISSN: 10736085     EISSN: None     Source Type: Journal    
DOI: 10.1385/MB:30:2:103     Document Type: Article

References (30)

1. Metcalf, D., Begley, C. G., Johnson, G. R., et al. (1986) Biologic properties in vitro of a recombinant human granulocyte-macrophage colony-stimulating factor. Blood 67, 37-45.
2. Armitage, J. (1998) Emerging applications of recombinant human granulocyte-macrophage colony-stimulating factor. Blood 92, 4491-4508.
3. Greenberg, P., Advani, R., Keating, A., ET AL. (1996) GM-CSF accelerates neutrophil recovery after autologous hematopoietic stem cell transplantation. Bone Marrow Transpl. 18, 1057-1064.
4. Anderson, J. E. and Appelbaum, F. R. (1994) Hematopoietic effects and clinical uses of granulocyte-macrophage colony-stimulating factor and PIXY321. Curr. Opin. Hematol. 1, 203-209.
5. Smith, T. and Grossberg, H. (1990) Successful use of granulocyte- macrophage colony-stimulating factor in patients with acute lymphocytic leukemia. Am. J. Med. 89, 384-386.
6. Nemunaitis, J., Gordon, A., Cox, J., ET AL. (1994) Phase II pilot trial comparing neutrophil and monocyte function by microbicidal assay in oncology patients receiving rhG-CSF, rHuGM-CSF or no cytokine after cytotoxic chemotherapy. Blood 84, 135.
7. Rowe, J. M., Rubin, A., Mazza, J. J., et al. (1996) Incidence of infections in adult patients (>55 years) with acute myeloid leukemia treated with yeast-derived GM-CSF (sargramostim): results of a double-blind prospective study by the Eastern Cooperative Oncology Group, in Acute Leukemias V: Experimental Approaches and Management of Refractory Disease (Hiddemann W., ed.). Springer-Verlag, Berlin, Germany, pp. 178.
8. Bodey, G. P., Anaissie, E., Gutterman, J., and Vadhan-Raj, S. (1993) Role of granulocyte-macrophage colony-stimulating factor as adjuvant therapy of fungal infection in patients with cancer. Clin. Infect. Dis. 17, 705-707.
9. Dranoff, G., Jaffee, E., Lazenby, A., et al. (1993) Vaccination with irradiated tumor cells engineered to secrete murine granulocyte-macrophage colony-stimulating factor stimulates potent, specific, and long-lasting anti-tumor immunity. Proc. Natl. Acad. Sci. 90, 3539-3543.
10. Spitler, L. E., Grossbard, M. L., Ernstoff, M. S.,et al. (1997) Adjuvant therapy of stage III and IV malignant melanoma using yeast derived, GM-CSF. Melanoma Res. 7, 160.
11. Chachoua, A., Oratz, R., Liebes, L., et al. (1994) Phase IB trial of granulocyte-macrophage colony-stimulating factor combined with murine monoclonal antibody R24 in patients with metastatic melanoma. J. Immunother. Emphasis Tumor Immunol, 16, 132-141.
12. Yu, A. L., Batova, A., Alvarado, C., Rao, V. J., and Castleberry, R. P. (1997) Usefulness of a chimeric anti-GD2 (ch14.18) and GM-CSF for refractory neuroblastoma: a POG phase II study. Proc. Am. Soc. Clin. Oncol. 16, 513a.
13. Costello, R. T. (1993) Therapeutic use of granulocyte-macrophage colony-stimulating factor (GM-CSF). A review of recent experience. Acta Oncol. 32, 403-408.
14. Berges, H., Joseph-Liauzun, E., and Fayet, O. (1996) Combined effects of the signal sequence and the major chaperone proteins on the export of human cytokines in Escherichia coli. Appl. Environ. Microbiol. 62, 55-60.
15. Lundell, D., Lunn, C., Greenberg, R., et al. (1990) Exploiting the cell membrane for the production of heterologous proteins in Escherichia coli. Biotechnol. Appl. Biochem. 12, 567-578.
16. Gronski, P., Badziong, W., Habermann, P., et al. (1988) E. coli derived human granulocyte-macrophage colony-stimulating factor (rhGM-CSF) available for clinical trials. Behring. Inst. Mitt. 83, 246-249.
17. Wang, J., Zou, M., Huang, B., Zhang, M., and Mao, N. (1995) Molecular cloning and expression of human granulocyte-macrophage colony stimulating factor in Escherichia coli system. Chin. J. Biotechnol. 11, 45-81.
18. Ling, M., Zou, M., Xu, M., Wang, J., and Ma, X. (1995) Purification of recombinant human granulocyte-macrophage colony stimulating factor expressed in Escherichia coli. Chin. J. Biotechnol. 11, 157-162.
19. Hua, Z., Wang, H., Chen, D., Chen, Y., and Zhu, D. (1994) Enhancement of expression of human granulocyte-macrophage colony stimulating factor by argU gene product in Escherichia coli. Biochem Mol Biol Int. 32, 537-543.
20. Pluckthun, A. (1992) Mono- and bivalent antibody fragments produced in Escherichia coli: engineering, folding and antigen binding. Immunol. Rev. 130, 151-188.
21. Bachmair, A., Finley, D., and Varshavsky, A. (1986) In vivo half-life of a protein is a function of its amino-terminal residue. Science 234, 179-186.
22. Nygren, P. A., Stahl, S., and Uhlen, M. (1994) Engineering proteins to facilitate bioprocessing. Trends Biotechnol. 12, 184-188.
23. Ujihara, M., Nomura, K., Yamada, O., Shibata, N., Kobayashi, M., and Takano, K. (2001) Granulocyte-macrophage colony-stimulating factor ensures macrophage survival and generation of the superoxide anion: a study using a monocytic-differentiated HL60 subline. Free Radic. Biol. Med. 31, 1396-1404.
24. Sorensen, M. A., Kurland, C. G., and Pedersen, S. (1989) Codon usage determines translation rate in Escherichia coli. J. Mol. Biol. 207, 365-377.
25. Zhang, S. P., Zubay, G., and Goldman, E. (1991) Low-usage codons in Escherichia coli, yeast, fruit fly and primates. Gene 105, 61-72.
26. Petrovskaia, L. E., Kriukov, E. A., Iakimov, S. A., et al. (1995) Effect of the topography of the signal peptidase site on the effectiveness of secretion of recombinant human granulocyte-macrophage colony-stimulating factor into Escherichia coli periplasm. Bioorg. Khim. 21, 912-919.
27. Hua, Z., Jie, L., and Zhu, D. (1994) Expression of a biologically active human granulocyte-macrophage colony stimulating factor fusion protein in Escherichia coli. Biochem. Mol. Bio. Int. 34, 621-626.
28. Eliseev, R., Alexandrov, A., and Gunter, T. (2004) High-yield expression and purification of p18 form of Bax as an MBP fusion protein. Protein Exp. Purification 35, 206-209.
29. 6-Tag and maltose-binding protein double-affinity fusion system. Protein Exp. Purification 10, 309-319.
30. Guan, M., Su, B., Ye, C., and Yuan L. (2002) Production of extracellular domain of human tissue factor using maltose-binding protein fusion system. Protein Exp. Purification 26, 229-234.